Clinical Trials

Date: 2018-01-04

Type of information: Initiation of development program


Announcement: initiation of development program

Company: Adocia (France)

Product: BioChaperone® glucagon exenatide

Action mechanism:

  • peptide/hormone. The BioChaperone proprietary technology enables the solubilization and stabilization of human glucagon at neutral pH. A liquid formulation of human glucagon may have utility as a ready to-inject treatment for severe hypoglycemia as well as in a dual hormone artificial pancreas (DHAP), i.e. a fully automated pump that would deliver both insulin and glucagon as a function of the person’s real-time glycaemia.
  • Human glucagon is the only product approved as an emergency treatment for severe hypoglycemia. Currently available emergency kits consist of lyophilized human glucagon for reconstitution immediately prior to injection (two available brands: GlucaGen HypoKit, Novo Nordisk and Glucagon, Eli Lilly). The usability of these kits, however, is poor as demonstrated in several clinical studies, due to the numerous steps required for reconstitution and administration. Therefore, there is a strong medical need for a ready-to-use solution in an auto-injector to simplify the injection and ensure the administration of the appropriate dose in an emergency situation. Adocia’s aqueous formulation of human glucagon could address the medical need for a readyto-use product for rescue from severe hypoglycemia and unlock the use of human glucagon as a chronic treatment in a DHAP. Adocia’s formulation strategy builds on the established safety and efficacy data sets for human glucagon.
  • Glucagon-like peptide-1 (GLP-1) is an incretin hormone that stimulates the secretion of insulin from the pancreas. Exenatide, a GLP-1 analog, is currently marketed in injectable form only, and is indicated for treatment of type 2 diabetes. Exenatide induces insulin release at increased glucose levels and causes a feeling of satiety, which results in reduced food intake and weight loss.

Disease: obesity

Therapeutic area: Metabolic diseases


Trial details:

Latest news:

  • • On January 4, 2018, Adocia announced an update of its corporate strategy. The company is now expanding application of its proprietary BioChaperone® technology beyond diabetes. Adocia is now applying this technology to glucagon and exenatide for the treatment of obesity. The project is based on BioChaperone Glucagon, a ready-to-inject formulation of human glucagon, for which positive Phase 1 topline results were recently announced by Adocia. The program is now in preclinical testing.

Is general: Yes